Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 16/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17656891 | 0.86 | MAP4K4 (0.49) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17249514 | 0.86 | PI4KA (0.48) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23869961 | 0.83 | MAP4K4 (0.47) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6957590 | 0.80 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL17562165 | 0.80 | IRAK4 (0.47) | MAP4K4IRAK4 | |
| SCHEMBL14566483 | 0.79 | IRAK4 (0.46) | MAP4K4IRAK4 | |
| SCHEMBL17132533 | 0.76 | IRAK4 (0.44) | MAP4K4IRAK4 | |
| SCHEMBL685458 | 0.76 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31216400 | 0.76 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25556184 | 0.75 | NR4A2 (0.56) | MAP4K4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023086428-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | MAP4K4 35/4885PI4KA 90/4885PI4K2B 196/4885 |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | MAP4K4 35/4885PI4KA 90/4885PI4K2B 196/4885 |
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | MAP4K4 104/4885PI4KA 335/4885PI4K2B 559/4885 |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP4K4 147/4885PI4KA 247/4885PI4K2B 251/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | MAP4K4 104/4885PI4KA 335/4885PI4K2B 559/4885 |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | NFKBIA, IKBKB, CHUK | MAP4K4 113/4885PI4KA 397/4885PI4K2B 844/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | MAP4K4 147/4885PI4KA 247/4885PI4K2B 251/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP4K4 147/4885PI4KA 247/4885PI4K2B 251/4885 |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP4K4 147/4885PI4KA 247/4885PI4K2B 251/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | MAP4K4 35/4885PI4KA 90/4885PI4K2B 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.